Abstract
You have accessJournal of UrologyUrodynamics/Incontinence/Female Urology: Non-Neurogenic Voiding Dysfunction1 Apr 20121956 LONG TERM INTERSTIM THERAPY EFFICACY IN A SINGLE TERTIARY CENTER COHORT OF 217 PATIENTS Karlien Peeters, Dirk de Ridder, and Frank van der Aa Karlien PeetersKarlien Peeters Leuven, Belgium More articles by this author , Dirk de RidderDirk de Ridder Leuven, Belgium More articles by this author , and Frank van der AaFrank van der Aa Leuven, Belgium More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2012.02.2115AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES We present overall long term followup data on the efficacy of Interstim Therapy in a cohort of 217 patients. All patients suffered voiding dysfunction, refractory to any of the previous offered therapies. METHODS This is a retrospective single tertiary center study including all the patients who received an implantable neurostimulator (Interstim therapy) between 1996 and 2010. In total we reviewed the data of 217 patients (86 % female), median age of implantation was 50.3 years (21-81 years old). 66 (30 %) patients suffered from urgency incontinence, 38 patients had urgency (17.5 %), 94 (43 %) had idiopathic retention (32 patients with Fowler, 62 non-Fowler). 1 patient had an implant because of enuresis nocturna, 10 patients had neuropathic bladder (multiple sclerosis) and 8 patients had painful bladder syndrome. RESULTS Longitudinal followup data of all implanted cases were analysed. Our median length of followup was 46.88 months (2.3-188 months). During followup, Interstim therapy was considered successful if the initial 50 % or more improvement in any of primary voiding diary variables persisted compared to baseline. If patients did not meet these criteria, therapy was considered a failure at that timepoint. After a median followup of 47 months,our overall success rate was 71 %. In the idiopathic retention group, we had 27 % failures. Patients with urgency incontinence had 30.3 % failures in the long term followup, whereas patients with urgency/frequency had 32.2 % failures. On Kaplan-Meier survival analysis, there is a better survival with Interstim therapy in patients treated for idiopathic retention (fowler and non-fowler) in comparison with patients treated for overactive bladder problems (urgency incontinence and urgency). This difference was statistically significant (p= 0.02). CONCLUSIONS This retrospective long term followup study on Interstim therapy shows an overall efficacy of 71 % in a large patient cohort. Interstim therapy remains a good option with long term results in a well selected patient population suffering from refractory voiding dysfunction. Patients with idiopathic retention seems to have statistically significant better survival results than patients with overactive bladder problems. The analysis of intervention rates on this population is performed in a separate analysis. © 2012 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 187Issue 4SApril 2012Page: e789 Advertisement Copyright & Permissions© 2012 by American Urological Association Education and Research, Inc.MetricsAuthor Information Karlien Peeters Leuven, Belgium More articles by this author Dirk de Ridder Leuven, Belgium More articles by this author Frank van der Aa Leuven, Belgium More articles by this author Expand All Advertisement Advertisement PDF DownloadLoading ...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.